[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.157.19.94. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Archives CME
September 1999

Archives of NeurologyReader's Choice: Continuing Medical Education

Author Affiliations
 

MATTHEWMENKENMD

Arch Neurol. 1999;56(9):1169-1171. doi:10.1001/archneur.56.9.1169
Physicians in the United States, Canada, and Mexico

Physicians with current and valid licenses in the United States, Canada, or Mexico who read any 3 of the selected continuing medical education (CME) articles in this issue of Archives of Neurology, complete the CME Evaluation Form, and fax it to the number or mail it to the address at the bottom of the CME Evaluation Form are eligible for category 1 CME credit. There is no charge.

The American Medical Association (AMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The AMA designates this educational activity for up to 3 hours of category 1 CME credit per Archives of Neurology issue toward the AMA Physician's Recognition Award (PRA). Each physician should claim only those hours of credit that were actually spent in this educational activity.

Physicians in Other Countries

Physicians with current and valid licenses in the United States, Mexico, or Canada are eligible for CME credit even if they live or practice in other countries. Physicians licensed in other countries are also welcome to participate in this CME activity. However, the PRA is only available to physicians licensed in the United States, Canada, or Mexico.

Statement of Educational Purpose

The Archives of Neurologyprovides new evidence for the practice of neurology, neurosurgery, and other specialties whose goal is to improve the neurological health of all people. Original contributions, neurological reviews, neurology and public health, and history of neurology are among the categories of articles published, but all contributions receive a sympathetic reading by the Chief Editor. The journal's editorial board sets the initial framework for the types of articles published, which is then modified by feedback from editors, external peer reviewers, authors, and readers. We are keen to receive submissions from practicing neurologists to provide new insight for colleagues.

We want our readers to assess each article critically; this CME activity is active, not passive. Does the article contribute in some way to the practice of neurology? How could you modify your practice style to incorporate what you have learned? How can you acquire more information, challenge the authors' conclusions, or verify what you have read? Which of the articles in each issue is least helpful in your quest for the best and most applicable evidence?

Earning Credit and CME Evaluation Form

To earn 1 hour of category 1 CME credit, you should read any 3of the CME articles listed and complete the CME Evaluation Form. To earn 3 hours of credit, read allof the articles listed and complete the CME Evaluation Form. The CME Evaluation Form must be submitted within 4 weeks of the issue date. A certificate awarding up to 3 hours of category 1 CME credit will be faxed or mailed to you; it is then your responsibility to maintain a record of credit received.

CME Articles in This Issue of Archives of Neurology

The articles listed below may be read for CME credit.

Stereotactic Pallidotomy in the Treatment of Parkinson Disease: An Expert OpinionArticle

Educational Objective:To read consensus recommendations for pallidotomy in Parkinson disease.

When to Start and Stop Anticonvulsant Therapy in ChildrenArticle

Educational Objective:To learn how long to treat children with anticonvulsants.

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis TherapeuticsArticle

Educational Objective:To learn about the use of disease-modifying drugs in multiple sclerosis.

Dipyridamole Plus Aspirin in Cerebrovascular DiseaseArticle

Educational Objective:To read about a meta-analysis of dipyridamole and aspirin in stroke prevention.

Heparin in Acute Stroke With Atrial Fibrillation: Clinical Relevance of Very Early TreatmentArticle

Educational Objective:To clarify when to use heparin in acute strokes.

Coagulation Activation in Patients With Binswanger DiseaseArticle

Educational Objective:To understand the association of Binswanger disease and coagulation-fibrinolysis pathway activation.

Deposition of β-Amyloid Subtypes 40 and 42 Differentiate Dementia With Lewy Bodies From Alzheimer DiseaseArticle

Educational Objective:To increase understanding of the neurobiology of beta-amyloid in neurodegenerative diseases.

Brain Choline Acetyltransferase and Mental Function in Alzheimer DiseaseArticle

Educational Objective:To understand the relationship between cognitive function and cholinergic system degeneration.

Differential Genetic Influence for Components of Memory in Aging Adult TwinsArticle

Educational Objective:To recognize the contributions of genetic and environmental factors to verbal memory.

The Influence of Handedness on the Clinical Presentation and Neuropsychology of Alzheimer DiseaseArticle

Educational Objective:To recognize the difference in clinical presentation and neuropsychological test performance of right- and left-handed people with Alzheimer disease.

Multiple Sclerosis That Is Progressive From the Time of Onset: Clinical Characteristics and Progression of DisabilityArticle

Educational Objective:To recognize the characteristics of multiple sclerosis progressive from onset.

Neurologic Nonmetabolic Presentation of Propionic AcidemiaArticle

Educational Objective:To recognize patients with propionic acidemia without episodes of ketoacidosis.

Oculoleptomeningeal Amyloidosis Associated With a New Transthyretin Variant Ser64Article

Educational Objective:To read about the neurogenetics of oculoleptomeningeal amyloidosis.

×